Last reviewed · How we verify
High Dose Corticosteroid
High-dose corticosteroids suppress immune system activity by inhibiting inflammatory cytokine production and reducing immune cell activation.
High-dose corticosteroids suppress immune system activity by inhibiting inflammatory cytokine production and reducing immune cell activation. Used for Severe inflammatory or autoimmune conditions (specific indication unknown from phase 3 context).
At a glance
| Generic name | High Dose Corticosteroid |
|---|---|
| Sponsor | University of Oxford |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Corticosteroids bind to glucocorticoid receptors in the cytoplasm, translocating to the nucleus to modulate gene expression. This leads to decreased production of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), reduced immune cell proliferation and migration, and suppression of both innate and adaptive immune responses. High doses amplify these immunosuppressive effects.
Approved indications
- Severe inflammatory or autoimmune conditions (specific indication unknown from phase 3 context)
Common side effects
- Hyperglycemia
- Hypertension
- Immunosuppression/increased infection risk
- Osteoporosis
- Mood disturbances
- Insomnia
Key clinical trials
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (PHASE1, PHASE2)
- MAGIC Ruxolitinib for aGVHD (PHASE2)
- Steroid Sparing in Immune Related Hepatitis (irH) (NA)
- Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment (PHASE3)
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |